Apalutamide not checked
Janssen Research & Development, LLC · JNJ 56021927 · ARN-509
FollowEvery change as it happens, and a Monday email
Trials
26 active
38 in total · 22 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “240 mg tablets administered by mouth on a continuous once daily dosing regimen”In the company’s words, NCT01946204 on ClinicalTrials.gov
- Tested for
- Prostatic Neoplasms (8 trials), Prostate Cancer, Metastatic Castrate-sensitive Prostate Cancer, Salivary Gland Neoplasms, Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Neoplasms and 1 more
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.”In the company’s words, NCT01946204 on ClinicalTrials.gov
- Other names
- JNJ 56021927 · ARN-509 · JNJ-56021927 and ARN-509
Other drugs for Prostatic Neoplasms
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJanssen Research & Development, LLC · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
- Aglatimagene besadenovecCandel Therapeutics · Phase 3
Coming up6
- 1 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 1 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 21 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 27 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials38
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 19 May 2017 | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer | |
| Phase 3Active, not recruiting | 19 Mar 2018 | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Phase 3Active, not recruiting | 7 Sep 2020 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC | |
| Phase 3Active, not recruiting | 12 Oct 2026 | A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC | |
| Phase 3Active, not recruiting | 1 Dec 2026 | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | |
| Phase 3Active, not recruiting | 1 Mar 2027 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | |
| Phase 3Active, not recruiting | 27 Aug 2029 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | |
| Phase 2Active, not recruiting | 9 Jun 2021 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | |
| Phase 1Active, not recruiting | 27 Jun 2016 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Active, not recruiting | 7 Nov 2016 | A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer | |
| Phase 1Active, not recruiting | 9 Jul 2019 | A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Active, not recruiting | 31 Dec 2026 | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer | |
| Phase 1Recruiting | 21 Jun 2027 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | |
| Phase 1Recruiting | 31 Aug 2027 | A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | |
| Phase 4Completed | 1 Jun 2023 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | |
| Phase 2Completed | 23 Oct 2023 | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | |
| Phase 1/2Completed | 20 Aug 2012 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | |
| Phase 1Completed | 10 May 2014 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | |
| Phase 1Completed | Nov 2014 | Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants | |
| Phase 1Completed | 20 Sep 2016 | A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | |
| Phase 1Completed | 9 Feb 2017 | A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function | |
| Phase 1Completed | 11 Apr 2019 | A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants | |
| Phase 1Completed | 11 Nov 2021 | A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Terminated | 30 Sep 2022 | A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Phase 1Completed | 10 Feb 2025 | A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function | |
| Phase 2Authorised | not given | "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN". | |
| Phase 3Authorised | not given | Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial | |
| Phase 3Authorised | not given | Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial | |
| Phase 3Authorised | not given | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) | |
| Phase 3Authorised | not given | ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | |
| Phase 2Ended | not given | A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer | |
| Phase 2Authorised | not given | A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy | |
| Phase 2Authorised | not given | A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy | |
| Phase 3Authorised | not given | CARLHA-2_AN OPEN LABEL, RANDOMIZED, PHASE III STUDY EVALUATING THE EFFICACY OF ACOMBINATION OF APALUTAMIDE WITH RADIOTHERAPY AND LHRH AGONIST IN HIGH-RISK POST-PROSTATECTOMY BIOCHEMICALLY RELAPSED PROSTATE CANCER PATIENTS | |
| Phase 2Authorised | not given | Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and staged as oligometastatic with PSMA-PET (STAPLE) | |
| Phase 2Authorised | not given | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile | |
| Phase 2Authorised | not given | AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) | |
| Phase 3Authorised | not given | Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026